Business
PDS Announces Release of PDS0101 Interim Data
PDS Announces Release of PDS0101 Interim Data.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2062B\n NetScientific PLC\n 08 June 2021\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\", the \"Group\" or the \"Company\")\n \n \n \n \n \n PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting\n \n \n \n \n \n \n London, UK - 8 June 2021\n \n - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), today announced the presentation of interim data from the Phase 2 trial led by the National Cancer Institute (NCI), of the National Institutes of Health (NIH), at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.\n \n \n \n \n The Phase 2 trial (NCT04287868) studies PDS0101 (Versamune®-HPV16) in combination with two investigational immune-modulating agents: bintrafusp alfa (M7824), a bifunctional \"trap\" fusion protein targeting TGF-β and PD-L1, and NHS-IL12 (M9241), a tumour-targeting immunocytokine. PDS0101 is an immunotherapy candidate designed to treat cancers caused by infection with HPV16 (HPV16-positive cancers) by activating the immune system to produce in vivo CD8+ (killer) T-cells to target and kill tumours that are HPV16-positive. Analyses of immune responses and other immune correlates are ongoing.\n \n \n \n \n \n Dr. Lauren Wood, Chief Medical Officer of PDS Biotechnology, commented:\n \n \n \"The achievement of a 67% tumour reduction among all HPV16-positive cancer patients including both CPI naïve and CPI refractory patients continues to strengthen the evidence supporting continuing clinical investigation of novel Versamune® platform's potential ability to induce high levels of tumour-specific CD8+ killer T-cells that attack the cancer in which we believe results in a strong synergy with bintrafusp alfa and NHS-IL12. The data provide early evidence of notable clinical activity, and we saw effective tumour regression in these patients\"\n \n \n \n \n \n \n \"The interim data demonstrating that this response was limited only to patients with HVP16-positive cancer, and also the fact that all responding patients who have stayed on treatment continue to show ongoing...